Compare AZIO & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZIO | MRKR |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 19.5M |
| IPO Year | 2014 | 2010 |
| Metric | AZIO | MRKR |
|---|---|---|
| Price | $0.53 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.87 |
| AVG Volume (30 Days) | ★ 343.4K | 182.9K |
| Earning Date | 11-20-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,939,008.00 | N/A |
| Revenue This Year | N/A | $19.61 |
| Revenue Next Year | N/A | $375.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 217.58 | N/A |
| 52 Week Low | $0.67 | $0.84 |
| 52 Week High | $1.84 | $2.46 |
| Indicator | AZIO | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 30.26 | 43.00 |
| Support Level | N/A | $0.88 |
| Resistance Level | $1.45 | $1.32 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 3.03 | 11.34 |
Azio AI Holdings Inc is a technology infrastructure company focused on developing, owning, and operating artificial intelligence data centers, enterprise GPU compute infrastructure, digital power solutions, and digital asset mining operations. The company operates an integrated AI infrastructure business encompassing AI data center development, the sale and distribution of enterprise GPU systems and server infrastructure, high-performance computing solutions, power hosting, and strategic technology investments, serving enterprise and institutional customers across domestic and international markets.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).